Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis | Critical Care Medicine | JAMA jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.
Read Time:
Researchers at the Lady Davis Institute (LDI) at the Jewish General Hospital have discovered that increased levels of the protein OAS1 are associated with reduced mortality and less severe disease requiring ventilation among patients with COVID-19. Using drugs that boost OAS1 levels could be explored to try to improve these outcomes. The findings are published today in
âOur analysis shows evidence that OAS1 has a protective effect against COVID-19 susceptibility and severity,â explains Dr. Brent Richards, a senior investigator at the LDIâs Centre for Clinical Epidemiology and Professor of Medicine, Human Genetics, Epidemiology and Biostatistics at McGill University. âThis is a very exciting development in the race to identify potential therapies to treat patients because there are already therapies in pre-clinical development that boost OAS1 and could be explored for their effect against SARS-CoV-2 infection.â
E-Mail
Researchers at the Lady Davis Institute (LDI) at the Jewish General Hospital have discovered that increased levels of the protein OAS1 are associated with reduced mortality and less severe disease requiring ventilation among patients with COVID-19. Using drugs that boost OAS1 levels could be explored to try to improve these outcomes. The findings are published today in
Nature Medicine. Our analysis shows evidence that OAS1 has a protective effect against COVID-19 susceptibility and severity, explains Dr. Brent Richards, a senior investigator at the LDI s Centre for Clinical Epidemiology and Professor of Medicine, Human Genetics, Epidemiology and Biostatistics at McGill University. This is a very exciting development in the race to identify potential therapies to treat patients because there are already therapies in pre-clinical development that boost OAS1 and could be explored for their effect against SARS-CoV-2 infection.
Neanderthal-derived protein may protect against COVID-19 susceptibility and severity news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.